Cediranib maleate is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cediranib maleate LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cediranib maleate overview

Cediranib (AZD2171, Recentin) is under development for the treatment of triple-negative breast cancer, pancreatic ductal adenocarcinoma (PDAC), small-cell lung cancer, cervical cancer, platinum-sensitive relapsed epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer. The drug candidate is administered orally as a coated tablet. It targets all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases.

It was also under development for the treatment of endometrial cancer, colorectal cancer, glioblastoma multiforme (GBM), gastrointestinal stromal tumors (GIST), renal cell carcinoma, solid tumors, non-small cell lung cancer, liver diseases, acute myelocytic leukemia (AML), head and neck cancer, alveolar soft part sarcoma, thyroid cancer and prostate cancer, breast cancer, malignant pleural mesothelioma.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

For a complete picture of Cediranib maleate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.